What is OncoTartis?
Founded in 2011, OncoTartis operates at the intersection of advanced molecular biology and oncology. The company utilizes its proprietary TARTIS platform to identify and develop small molecule inhibitors designed to address high-unmet-need areas in cancer treatment, including breast, prostate, and hematological malignancies. Its lead candidate, OT-82, a potent NAMPT inhibitor, represents the core of its current clinical efforts, having entered Phase 1/2a trials in 2019. By focusing on specific metabolic vulnerabilities, OncoTartis distinguishes itself from traditional broad-spectrum therapeutic developers, aiming to provide more precise interventions for patients facing aggressive disease profiles.
How much funding has OncoTartis raised?
OncoTartis has raised a total of $6.1M across 2 funding rounds:
Unspecified
$6M
Debt
$57K
Unspecified (2017): $6M with participation from Pharmstandard International S.A.
Debt (2021): $57K led by PPP
Key Investors in OncoTartis
Pharmstandard International S.A.
A Russia-based pharmaceutical entity focused on the manufacturing, wholesale distribution, and biotechnological research of medical products.
PPP
Public-Private Partnership
What's next for OncoTartis?
With the recent capital injection, OncoTartis is well-positioned to accelerate its clinical trial roadmap and refine its drug discovery capabilities. The strategic focus remains on the successful execution of the ongoing Phase 1/2a study for OT-82, which serves as a primary value driver for the company. As the firm moves forward, management is expected to prioritize data readout milestones and potential collaborative opportunities to further validate the TARTIS platform. The current funding trajectory suggests a transition from early-stage research toward more robust clinical validation, setting the stage for potential future licensing agreements or strategic partnerships within the global pharmaceutical landscape.
See full OncoTartis company page
